IDNLearn.com: Your one-stop platform for getting reliable answers to any question. Get accurate and timely answers to your queries from our extensive network of experienced professionals.
The targeting of the BCR-ABL fusion protein for Chronic Myeloid Leukemia (CML) was a departure from previous cancer chemotherapies because: a. It targeted a protein unique to a specific cancer, rather than fundamental universal cellular process. b. It was the first drug to be approved from a High-Throughput Screening campaign. c. It was the first drug to be approved that originated in a rational drug design effort (using crystal structures to guide design). d. It has the fastest approval time from initial target ID to treatment of patients of any drug to date.
Sagot :
Your engagement is important to us. Keep sharing your knowledge and experiences. Let's create a learning environment that is both enjoyable and beneficial. Your search for solutions ends at IDNLearn.com. Thank you for visiting, and we look forward to helping you again.
